E. M. Rivero

Prognostic significance of α‐ and β2‐adrenoceptor gene expression in breast cancer patients

A. Bruzzone, E. M. Rivero, L. Martinez, 2019, British journal of clinical pharmacology.

Increased delivery of chemotherapy to the vitreous by inhibition of the blood‐retinal barrier

J. Mora, M. Torrebadell, A. Carcaboso, 2017, Journal of controlled release : official journal of the Controlled Release Society.

Agonist Effects of Propranolol on Non-Tumor Human Breast Cells

A. Bruzzone, C. Davio, M. Buffone, 2020, Cells.

Differential β2-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines

S. Copsel, A. Bruzzone, C. Davio, 2014, Oncotarget.

Synthesis and biological evaluation of salpichrolide analogs as antiestrogenic agents.

G. Burton, E. M. Rivero, L. Gargiulo, 2014, European journal of medicinal chemistry.

A Novel Effect of β-Adrenergic Receptor on Mammary Branching Morphogenesis and its Possible Implications in Breast Cancer

S. Copsel, A. Bruzzone, M. May, 2017, Journal of Mammary Gland Biology and Neoplasia.

Alpha2-adrenoceptor agonists trigger prolactin signaling in breast cancer cells.

V. Goffin, E. M. Rivero, I. Lüthy, 2017, Cellular signalling.

The β 2-Adrenergic Agonist Salbutamol Inhibits Migration, Invasion and Metastasis of the Human Breast Cancer MDA-MB- 231 Cell Line.

A. Bruzzone, K. Zänker, F. Entschladen, 2017, Current cancer drug targets.

The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models

A. Bruzzone, E. M. Rivero, I. Lüthy, 2023, Cancer Chemotherapy and Pharmacology.